Design, Synthesis, and Structure–Activity Relationship Study of Potent MAPK11 Inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target for HD. Regrettably, no MAPK11 small molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Mengdie, Tu, Mingyan, Sun, Hongxia, Li, Lu, Zhu, Lili, Li, Honglin, Zhao, Zhenjiang, Li, Shiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746797/
https://www.ncbi.nlm.nih.gov/pubmed/35011435
http://dx.doi.org/10.3390/molecules27010203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746797/
https://www.ncbi.nlm.nih.gov/pubmed/35011435
http://dx.doi.org/10.3390/molecules27010203

Ejemplares similares